Emily Menendez

Emily Menendez is an assistant editor for GU Oncology Now and Cancer Nursing Today. She uses her copywriting experience to contribute content on the latest updates in the oncology nursing sphere. Ms. Menendez received her BA from the University of Central Florida.

Articles by Emily Menendez

Emily MenendezTesticular, Penile, and Rare Malignancies | September 25, 2023
Patients with a complete resection at pcRPLND and <10% viable cells had favorable outcomes without any further treatment.
Read More
Emily MenendezLocalized Prostate Cancer | September 25, 2023
Bladder cancers that develop after radiation tend to be more aggressive and are more likely to be sarcomatoid variant.
Emily MenendezLocalized Prostate Cancer | September 25, 2023
Higher tumor fraction after chemohormonal therapy was also linked to aggressive pathologic features and poor outcomes.
Emily MenendezUpper Tract Urothelial Carcinoma | September 22, 2023
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Emily MenendezTesticular, Penile, and Rare Malignancies | September 15, 2023
The AUA released a new amendment to their 2019 guideline for the diagnosis and treatment of early-stage testicular cancer.
Emily MenendezAdvanced Urothelial Carcinoma | September 15, 2023
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Emily MenendeznccRCC | September 14, 2023
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
Emily MenendezTesticular, Penile, and Rare Malignancies | September 13, 2023
Newly identified risk factors could be used in future studies on risk-adapted follow-up and treatment strategies.
Emily MenendezmHSPC | September 13, 2023
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Emily MenendezLocalized Prostate Cancer | September 8, 2023
Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic.
Emily MenendezAdvanced Renal Cell Carcinoma | September 8, 2023
Improved PFS was associated with negative surgical margins and no 30-day surgical complications, plus pathologic downstaging.
Emily MenendezMuscle Invasive Urothelial Carcinoma | September 8, 2023
Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.
Emily MenendezUpper Tract Urothelial Carcinoma | September 8, 2023
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Emily MenendezRLT-PSMA | August 31, 2023
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
Emily MenendezmCRPC | August 31, 2023
As mCRPC cells are deficient in retinoblastoma proteins, they have a hypersensitivity to taxanes such as cabazitaxel.
Emily MenendezUromigos Live 2023 | August 29, 2023
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Emily MenendezmCRPC | August 29, 2023
The trial’s 2 primary end points were PFS and overall survival, with a secondary end point of objective response rate.
Emily MenendezAdvanced Urothelial Carcinoma | August 29, 2023
Somatic alterations in DDR genes are common in patients with advanced urothelial cancer.
Emily MenendezLocalized Renal Cell Carcinoma | August 28, 2023
While nephrectomy is a common treatment for kidney cancer, it can result in loss of kidney function or kidney failure.
Emily MenendezNext-Generation Imaging | August 28, 2023
The SOLAR trial aimed to evaluate the safety and biodistribution of Copper Cu 64 PSMA I&T to detect prostate cancer.